# A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

> **NCT04633447** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 53 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04633447
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-10
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-05-22
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** The study primary endpoint was not met
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04633447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04633447, "A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04633447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*